ZA964439B - Methods for inhibiting vascular smooth muscle cell migration. - Google Patents

Methods for inhibiting vascular smooth muscle cell migration.

Info

Publication number
ZA964439B
ZA964439B ZA9604439A ZA964439A ZA964439B ZA 964439 B ZA964439 B ZA 964439B ZA 9604439 A ZA9604439 A ZA 9604439A ZA 964439 A ZA964439 A ZA 964439A ZA 964439 B ZA964439 B ZA 964439B
Authority
ZA
South Africa
Prior art keywords
methods
smooth muscle
cell migration
muscle cell
vascular smooth
Prior art date
Application number
ZA9604439A
Other languages
English (en)
Inventor
Jai Pal Singh
Todd Robert Wiernicki
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA964439B publication Critical patent/ZA964439B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA9604439A 1995-06-01 1996-05-30 Methods for inhibiting vascular smooth muscle cell migration. ZA964439B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/457,700 US5622975A (en) 1995-06-01 1995-06-01 Methods for inhibiting vascular smooth muscle cell migration

Publications (1)

Publication Number Publication Date
ZA964439B true ZA964439B (en) 1997-12-01

Family

ID=23817780

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9604439A ZA964439B (en) 1995-06-01 1996-05-30 Methods for inhibiting vascular smooth muscle cell migration.

Country Status (20)

Country Link
US (1) US5622975A (fr)
EP (1) EP0745384A3 (fr)
JP (1) JPH11509836A (fr)
KR (1) KR19990022053A (fr)
CN (1) CN1089237C (fr)
AU (1) AU707756B2 (fr)
CA (1) CA2222292A1 (fr)
CZ (1) CZ287958B6 (fr)
EA (1) EA000190B1 (fr)
HU (1) HUP9900851A3 (fr)
IL (1) IL118483A (fr)
MY (1) MY112973A (fr)
NO (1) NO975369L (fr)
NZ (1) NZ309390A (fr)
PL (1) PL323786A1 (fr)
RO (1) RO117996B1 (fr)
UA (1) UA42835C2 (fr)
WO (1) WO1996038145A1 (fr)
YU (1) YU32196A (fr)
ZA (1) ZA964439B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5843974A (en) * 1995-06-06 1998-12-01 Eli Lilly And Company Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
JPH11510479A (ja) 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US5747509A (en) * 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
US6124260A (en) * 1998-09-30 2000-09-26 Cedars-Sinai Medical Center Inhibition of smooth muscle cell migration by Tenascin-C peptides
EP1175433B1 (fr) 1999-05-04 2005-08-03 Strakan International Limited Glycosides d'androgenes et activite androgenique desdits glycosides
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US8236048B2 (en) * 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20040243097A1 (en) * 2000-05-12 2004-12-02 Robert Falotico Antiproliferative drug and delivery device
US20020051730A1 (en) * 2000-09-29 2002-05-02 Stanko Bodnar Coated medical devices and sterilization thereof
EP1322235B2 (fr) 2000-09-29 2010-08-11 Cordis Corporation Dispositifs medicaux enrobes
US20020111590A1 (en) * 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US7108701B2 (en) * 2001-09-28 2006-09-19 Ethicon, Inc. Drug releasing anastomosis devices and methods for treating anastomotic sites
US20030065377A1 (en) * 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5457113A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
EP0664121B1 (fr) * 1993-12-21 2001-10-31 Eli Lilly And Company Utilisation du raloxifene et de ses analogues dans la fabrication d'un medicament pour le traitement de l'athérosclérose et la cardiopathie ischemique

Also Published As

Publication number Publication date
KR19990022053A (ko) 1999-03-25
EP0745384A3 (fr) 1997-02-26
YU32196A (sh) 1999-06-15
NZ309390A (en) 2000-07-28
CN1089237C (zh) 2002-08-21
AU707756B2 (en) 1999-07-22
UA42835C2 (uk) 2001-11-15
CZ374497A3 (cs) 1998-06-17
EA199700450A1 (ru) 1998-06-25
WO1996038145A1 (fr) 1996-12-05
RO117996B1 (ro) 2002-12-30
PL323786A1 (en) 1998-04-27
AU5954196A (en) 1996-12-18
EA000190B1 (ru) 1998-12-24
CA2222292A1 (fr) 1996-12-05
EP0745384A2 (fr) 1996-12-04
CZ287958B6 (cs) 2001-03-14
JPH11509836A (ja) 1999-08-31
NO975369D0 (no) 1997-11-21
NO975369L (no) 1997-11-21
MY112973A (en) 2001-10-31
US5622975A (en) 1997-04-22
MX9709189A (es) 1998-03-31
HUP9900851A3 (en) 1999-11-29
IL118483A (en) 2000-06-29
CN1191487A (zh) 1998-08-26
IL118483A0 (en) 1996-09-12
HUP9900851A2 (hu) 1999-09-28

Similar Documents

Publication Publication Date Title
ZA964439B (en) Methods for inhibiting vascular smooth muscle cell migration.
ZA961316B (en) Benzopyran-containing compounds and method for their use.
PL323178A1 (en) Schirophrenia diagnosin method
ZA967513B (en) Method of treating insulin resistance.
ZA969016B (en) Solubilisation methods.
DE69610844D1 (en) Hydroformylierungsverfahren.
GB9519638D0 (en) Method
GB9518442D0 (en) Method
ZA966603B (en) Therapeutic method.
GB2308522B (en) Redialling method
GB9601976D0 (en) Method
EP0667157A4 (fr) Traitement symptomatique des troubles circulatoires.
ZA966970B (en) Water treatment method.
GB9510727D0 (en) Method
ZA9610458B (en) Novel method.
GB9511828D0 (en) Method
ZA966699B (en) Substituted 2-phenylpyridines.
GB9722553D0 (en) Method
EP0722725A4 (fr) Inhibiteur de la migration cellulaire dans les muscles lisses vasculaires
ZA968524B (en) Therapeutic method.
AU6814294A (en) Inhibiting vascular smooth muscle cell proliferation
ZA962751B (en) Ascomycins.
GR950200165U (en) Rings for gymnastics.
GB9516970D0 (en) Methods
GB9516940D0 (en) Methods